NCT01887288终止2 期
Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Metronomic Capecitabine With Oral Digoxin
研究概览
简要总结
To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
详细描述
In this phase II study, the Investigators will combine metronomic capecitabine with digoxin to treat metastatic breast cancer patients who have progressed on both anthracyclines and taxanes. We hypothesize that the combination of digoxin with metronomic capecitabine may lead to increased efficacy and duration of treatment without progression with decreased side effects than standard regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years of age with histologically confirmed, metastatic breast cancer resistant to anthracyclines and taxanes
- •Anthracycline resistance is defined as tumor progression during treatment or within 3 months of last dose in the metastatic setting, or recurrence within 6 months in the neoadjuvant or adjuvant setting. Alternatively, a minimum cumulative dose of anthracycline of 240 mg/m^2 (doxorubicin) or 360 mg/m^2 (epirubicin) has been reached, or there is contraindication to use anthracycline, the patient is also eligible
- •Taxane resistance is defined as recurrence within 4 months of the last dose in the metastatic setting or within 12 months in the adjuvant setting
- •Having progressed on anti-HER2 or hormonal therapy if they have HER2 positive or hormone-receptor positive breast cancer
- •Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 and a life expectancy >3 months.
- •Participants must have at least one target lesion as defined by RECIST 1.1 that allows for evaluation of tumor response
- •Absolute neutrophil count ≥ 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5 g/dL
- •Serum creatinine ≤1.5 times the upper limit of the normal range, total bilirubin ≤ 2 mg/dL, AST/ALT ≤ 5 times the upper limit of normal range
- •No remaining grade 2 or higher toxicity from prior cancer therapies unless judged to be clinically insignificant by the Principal Investigator
- •At least three (3) weeks from prior chemotherapy
- •Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.
排除标准
- •Inadequate renal function with a calculated creatinine clearance less than 51 mL/min.
- •History of ventricular fibrillation, sinus node or AV nodal disease, Wolff Parkinson White Syndrome, hemodynamically significant or life threatening cardiac arrhythmia.
- •Uncontrolled cardiac disease, congestive heart failure, angina or hypertension.
- •Myocardial infarction or unstable angina within 2 months of treatment.
- •Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B or C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).
- •Active clinically serious infection > CTCAE (version 4.03) Grade
- •Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- •Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of study drug.
- •Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of study drug.
- •Serious non-healing wound, ulcer, or bone fracture.
- •Major surgery or significant traumatic injury within 2 weeks of first study drug.
- •Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
- •Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.
- •Currently on anti-coagulation therapy with Coumadin, and cannot be switched other forms of anti-coagulation.
- •Patients have symptomatic untreated brain metastasis or leptomeningeal metastases or treated but still symptomatic requiring the use of steroid within the past two weeks.
- •Patients receiving any other investigational agents. Pregnant or Lactating females.
研究组 & 干预措施
Capecitabine with Digoxin
Experimental
Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle
(1 cycle - 4 weeks)
干预措施: Capecitabine (Drug)
Capecitabine with Digoxin
Experimental
Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle
(1 cycle - 4 weeks)
干预措施: Digoxin (Drug)
结局指标
主要结局
Metronomic Capecitabine With Oral Digoxin
时间窗: One year
Evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
次要结局
- Combination Overall Clinical Benefit by RECIST 1.1(One year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast CancerBreast NeoplasmsNCT00191672Eli Lilly and Company120
招募中
2 期
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical TrialTriple Negative Breast CancerNCT05390476wang shusen126
已完成
2 期
Capecitabine in Treating Patients With Metastatic Breast CancerBreast CancerNCT00274768Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins26
进行中（未招募）
不适用
Metronomic Capecitabine plus Docetaxel as first line treatment for metastatic breast cancer patients: a phase II trial - NDMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticMetastatic breast cancerEUCTR2009-009937-14-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
1 期
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid TumorsMalignant NeoplasmasSolid TumorsNCT01125891Traws Pharma, Inc.39